Oncology Articles

Dacomitinib Stands Out in EGFR-Mutated Subtype Response
Second-generation EGFR inhibitor dacomitinib showed clear superiority over first-generation TKI gefitinib (Iressa) in a comparison of performance in EGFR mutation subtypes exon 19 deletion and L858R in advanced NSCLC.
Ramucirumab Associated With OS Benefit in Aggressive NSCLC
Ramucirumab (Cyramza) plus docetaxel demonstrated an overall survival benefit versus placebo plus docetaxel in patients with advanced NSCLC whose disease rapidly progressed on first-line therapy,
Expert Discusses Ongoing Advances in CLL
Farrukh Awan, MD, discusses novel agents and combinations in CLL, as well as the critical importance of FISH and IGHV testing for patient selection in this population.
Cabozantinib Improves Survival in Phase III HCC Trial
Cabozantinib (Cabometyx) improved overall survival versus placebo in patients with advanced hepatocellular carcinoma who have previously received sorafenib (Nexavar), meeting the primary endpoint of the phase III CELESTIAL trial.
Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC
A lower dose of ceritinib taken with a low-fat meal showed similar efficacy with fewer dose reductions and less severe gastrointestinal adverse events versus a 750-mg dose taken without food for patients with untreated ALK-positive metastatic non­–small cell lung cancer.
Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced an objective response rate of 46% in patients with recurrent small cell lung cancer with high tumor mutation burden, according to an exploratory analysis from the phase I/II CheckMate-032 study.
Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the existing marketing authorization for abiraterone acetate (Zytiga) in men with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer.
FDA Grants Priority Review to Frontline Cabozantinib in RCC
The FDA has granted a priority review to a supplemental new drug application for cabozantinib (Cabometyx) for previously untreated patients with advanced renal cell carcinoma.
FISHing for a Better Assay in ALK-Positive Lung Cancer
In addition to proving the superiority of alectinib versus crizotinib, the phase III ALEX trial provided clear guidance on which of 2 assays evaluated could provide stronger guidance on which patients would respond to ALK-specific therapy.
IASLC Conference Will Highlight PACIFIC Trial QoL Data on Durvalumab
Fred R. Hirsch, MD, PhD, provides highlights of the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer, leading with his excitement for updated quality-of-life data from the PACIFIC trial of patients with locally advanced, unresectable stage III non–small cell lung cancer.
Publication Bottom Border
Border Publication